Everest Medical
This article was originally published in The Gray Sheet
Executive Summary
Receives $800,000 equity investment from a private investor through the sale of 290,909 units at $2.75 each. The units consist of one share of unregistered common stock and one warrant to purchase a share of unregistered common stock for $3.50. The company had announced Jan. 21 that it was seeking financing from "numerous corporate and private sources" to continue operations ("The Gray Sheet" Feb. 1, p. 14). Everest Medical Chairman Michael Hollenhorst says in a Feb. 8 release that the recent investment "provides us with necessary working capital which will help us to cover operating expenses as we roll out our laparoscopic surgical scissors and forceps." The company "will require additional capital, which is being sought from various sources." The minimally invasive surgery products manufacturer says it has taken steps to "further reduce" its operating expenses and expects to make "additional spending and staff reductions." The company believes the reductions can be made "without significantly jeopardizing" sales and development activities. The firm also announced Feb. 8 that it has received notice from its Japanese distributor, Koshin International, that Japan's Ministry of Health has granted approval for Koshin to commence promotion and sales of Everest Medical's Evershears bipolar laparoscopic scissors in Japan.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.